Vergari E, Knudsen J, Ramracheya R, Salehi A, Zhang Q, Adam J
Nat Commun. 2019; 10(1):139.
PMID: 30635569
PMC: 6329806.
DOI: 10.1038/s41467-018-08193-8.
Hansen T, Vestergaard H, Jorgensen T, Jorgensen M, Lauritzen T, Brandslund I
BMC Med Genet. 2015; 16:17.
PMID: 25927630
PMC: 4422140.
DOI: 10.1186/s12881-015-0160-7.
Ludvigsson J
Diabetologia. 2009; 52(10):2245-6.
PMID: 19705101
DOI: 10.1007/s00125-009-1489-2.
Kim N, Kim D, Choi K, Baik S, Choi D
Korean J Intern Med. 2001; 15(3):195-201.
PMID: 11242807
PMC: 4531777.
DOI: 10.3904/kjim.2000.15.3.195.
Heding L, Tronier B
Int J Pancreatol. 1995; 17(2):167-71.
PMID: 7622939
DOI: 10.1007/BF02788535.
Growth hormone and metasomatotrophic diabetes: effects on insulin and proinsulin of serum and pancreas in dogs.
Pierluissi J, Campbell J
Diabetologia. 1981; 21(6):558-62.
PMID: 7040145
DOI: 10.1007/BF00281549.
Hypersecretion of proinsulin in thyrotoxicosis.
Sestoft L, Heding L
Diabetologia. 1981; 21(2):103-7.
PMID: 7021283
DOI: 10.1007/BF00251275.
B-cell function in newborn infants of diabetic mothers.
Heding L, Persson B, Stangenberg M
Diabetologia. 1980; 19(5):427-32.
PMID: 7004961
DOI: 10.1007/BF00281821.
Human proinsulin standards.
Kruse V, Heding L, Jorgensen K, Tronier B, Christensen M, Thim L
Diabetologia. 1984; 27(3):414-5.
PMID: 6500201
DOI: 10.1007/BF00304860.
Serum levels of true insulin, C-peptide and proinsulin in peripheral blood of patients with cirrhosis.
Heding L, Czyzyk A
Diabetologia. 1983; 25(6):506-9.
PMID: 6363178
DOI: 10.1007/BF00284460.
Pancreatic A and B cell hyperfunction in the Mendenhall syndrome.
Serrano Rios M, de la Vina S, Carbo M, Nash R, Barrio R, Heding L
Diabetologia. 1983; 25(1):8-12.
PMID: 6350087
DOI: 10.1007/BF00251888.
Prevalence of residual B cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetes.
Madsbad S
Diabetologia. 1983; 24(3):141-7.
PMID: 6341142
DOI: 10.1007/BF00250151.
Biochemical and clinical implications of proinsulin conversion intermediates.
Given B, Cohen R, Shoelson S, Frank B, Rubenstein A, Tager H
J Clin Invest. 1985; 76(4):1398-405.
PMID: 3902891
PMC: 424086.
DOI: 10.1172/JCI112116.
Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y
Diabetologia. 1988; 31(6):355-60.
PMID: 3046976
DOI: 10.1007/BF02341503.
Defective glucose utilization in patients with functioning beta-cell tumors persists after tumor excision.
McGee G, Kulaylat M, Abumrad N
Ann Surg. 1987; 206(4):449-57.
PMID: 2821936
PMC: 1493209.
DOI: 10.1097/00000658-198710000-00005.
The plasma C-peptide and insulin responses to stimulation with intravenous glucagon and a mixed meal in well-controlled type 2 (non-insulin-dependent) diabetes mellitus: dependency on acutely established hyperglycaemia.
GJESSING H, Reinholdt B, Pedersen O
Diabetologia. 1989; 32(12):858-63.
PMID: 2693165
DOI: 10.1007/BF00297450.
Controlled study comparing treatment with monocomponent insulin and conventional insulin in patients with lipoatrophy.
Czyzyk A, ROGALA H, LAWECKI J
Acta Diabetol Lat. 1989; 26(1):17-26.
PMID: 2665407
DOI: 10.1007/BF02581192.
Effect of insulin on renal sodium handling in hyperinsulinaemic type 2 (non-insulin-dependent) diabetic patients with peripheral insulin resistance.
Skott P, Vaag A, Bruun N, Hother-Nielsen O, Gall M, Beck-Nielsen H
Diabetologia. 1991; 34(4):275-81.
PMID: 2065862
DOI: 10.1007/BF00405088.
A novel point mutation in the human insulin gene giving rise to hyperproinsulinemia (proinsulin Kyoto).
Yano H, Kitano N, Morimoto M, Polonsky K, Imura H, Seino Y
J Clin Invest. 1992; 89(6):1902-7.
PMID: 1601997
PMC: 295889.
DOI: 10.1172/JCI115795.
Indirect two-site immunoradiometric assay of rat and mouse proinsulin.
Yue D, Gibby O, Luzio S, Yanaihara N, Hales C
Diabetologia. 1979; 17(4):235-42.
PMID: 91539
DOI: 10.1007/BF01235860.